Skip to main content
. 2017 Dec 21;12(12):e0190035. doi: 10.1371/journal.pone.0190035

Table 1. Participant demographics for those at risk of a first breakthrough seizure, n (%) unless otherwise stated.

Characteristic Arm A
(n = 1067)
Arm B
(n = 526)
Total
(n = 1593)
Male 609 (57) 314 (60) 923 (58)
Febrile Seizure History 61 (6) 44 (8) 105 (7)
Epilepsy in first degree relative 111 (10) 89 (17) 200 (13)
Neurological insult 104 (10) 52 (10) 156 (10)
Seizures
Simple or Complex Partial with Secondary Generalised Seizures 597 (56) 15 (3) 622 (39)
Simple or Complex Partial only 328 (31) 25 (4) 343 (22)
Generalised tonic-clonic seizures only 15 (1) 154 (29) 169 (11)
Absence seizures 2 (0) 82 (16) 84 (5)
Myoclonic or absence seizures with tonic- clonic seizures 3 (0) 106 (20) 109 (7)
Tonic-clonic seizures, uncertain if focal or generalised 113 (11) 114 (22) 227 (14)
Other 9 (1) 30 (6) 39 (2)
Epilepsy type
Partial 929 (87) 40 (8) 969 (61)
Generalised 21 (2) 357 (68) 378 (24)
Unclassified 117 (11) 129 (24) 246 (15)
EEG results
Normal 472 (44) 129 (25) 601 (38)
Non-specific Abnormality 180 (17) 55 (10) 235 (15)
Epileptiform Abnormality 328 (31) 321 (61) 649 (40)
Not donea 87 (8) 21 (4) 108 (7)
CT/MRI scan results
Normal 639 (60) 233 (44) 872 (55)
Abnormal 262 (25) 30 (6) 292 (18)
Not doneb 166 (15) 263 (50) 429 (27)
Drugs attempted to achieve 12-month remission
One 805 (75) 397 (75) 1202 (75)
Two or more 262 (25) 129 (25) 391 (25)
Number of tonic-clonic seizures ever from randomisation to achievement of 12-month remission, median (IQR) 2 (0, 4) 3 (1, 5) 2 (0, 5)
Age at achievement of 12-month remission (years),
median (IQR)
38 (25, 55) 20 (14, 30) 31 (19, 49)
Time to achieve 12-month remission from randomisation (years), median (IQR) 1.1 (1.0, 1.8) 1.1 (1.0, 1.8) 1.1 (1.0, 1.8)

aMost of these patients had focal epilepsy

bMost of these patients were aged < 20 years